| Literature DB >> 35351940 |
Samir El Qaidi1, Nichollas E Scott2, Michael P Hays1, Philip R Hardwidge3.
Abstract
The Salmonella enterica SseK1 protein is a type three secretion system effector that glycosylates host proteins during infection on specific arginine residues with N-acetyl glucosamine (GlcNAc). SseK1 also Arg-glycosylates endogenous bacterial proteins and we thus hypothesized that SseK1 activities might be integrated with regulating the intrabacterial abundance of UPD-GlcNAc, the sugar-nucleotide donor used by this effector. After searching for new SseK1 substrates, we found that SseK1 glycosylates arginine residues in the dual repressor-activator protein NagC, leading to increased DNA-binding affinity and enhanced expression of the NagC-regulated genes glmU and glmS. SseK1 also glycosylates arginine residues in GlmR, a protein that enhances GlmS activity. This Arg-glycosylation improves the ability of GlmR to enhance GlmS activity. We also discovered that NagC is a direct activator of glmR expression. Salmonella lacking SseK1 produce significantly reduced amounts of UDP-GlcNAc as compared with Salmonella expressing SseK1. Overall, we conclude that SseK1 up-regulates UDP-GlcNAc synthesis both by enhancing the DNA-binding activity of NagC and by increasing GlmS activity through GlmR glycosylation. Such regulatory activities may have evolved to maintain sufficient levels of UDP-GlcNAc for both bacterial cell wall precursors and for SseK1 to modify other bacterial and host targets in response to environmental changes and during infection.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35351940 PMCID: PMC8964723 DOI: 10.1038/s41598-022-09276-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1SseK1 glycosylates NagC and GlmR. (A) Schematic of NagC and Glm pathway under investigation. (B) Western blot analysis of intra-bacterial glycosylation of NagC, GlmS, GlmM, GlmU, and GlmR. (C) In vivo glycosylation of indicated proteins in wild-type Salmonella enterica and sseK mutants. (D). Western blot analysis of in vitro glycosylation of NagC and GlmR in the presence of active or inactive (HEN) forms of SseK1. (E) Mass spectrometry analysis of NagC Arg-glycosylation by SseK1. HCD spectra of the in vivo glycosylated NagC tryptic peptides containing glycosylated R54, R35, and R25. (F) Mass spectrometry analysis of GlmR Arg-glycosylation by SseK1. HCD spectra of the in vivo glycosylated GlmR GluC derived peptides containing glycosylated R212, and R110. (G) Western blot verification of Arg-glycosylation of WT and R-to-A point mutations of NagC. (H) Western blot verification of Arg-glycosylation of WT and R-to-A point mutations of GlmR.
Figure 2Arg-glycosylation of NagC enhances its DNA binding activity. (A) Quantification of GFP expression levels of nagB::gfp transcriptional fusions in wild-type Salmonella enterica and its ΔsseK1 or ΔnagC derivatives grown in M9 minimal medium supplemented with either 0.2% glucose or 0.2% GlcNAc as the sole carbon
source for 8 h. GFP levels are expressed as RFU (relative fluorescence units)/OD600 ratio. (B) Quantification of glmU::gfp transcriptional fusions. (C) SDS-PAGE and Western blot analysis of purified NagC and NagC-GlcNAc. (C) Purification of native and Arg-glycosylated NagC combined with validation of glycosylation by using Western blotting. (D) EMSAs comparing the DNA-binding activity of NagC and NagC-GlcNAc towards nagB promoter DNA. Two nmoles of Alexa fluor-labeled and then DNA–protein complexes were resolved on 0.5% agarose gels. (E) glmU EMSAs. (F) Quantification of binding affinities of native and Arg-glycosylated NagC to nagB promoter DNA. (G) Quantification of binding affinities of native and Arg-glycosylated NagC to glmU promoter DNA. (H) EMSAs comparing the DNA-binding activity of NagC, NagC-GlcNAc, and NagC (R–K) mutant towards nagB promoter DNA. Experiments were performed as described for panel D.
Figure 3NagC activates glmR. (A) Identification of a potential NagC binding site in the glmR promoter based on similarity to the glmU promoter. (B) Quantification of GFP expression levels of glmR::gfp transcriptional fusions in wild-type Salmonella enterica and its ΔsseK1 or ΔnagC derivatives grown in M9 minimal medium supplemented with either 0.2% glucose or 0.2% GlcNAc as the sole carbon
source for 8 h. GFP levels are expressed as RFU (relative fluorescence units)/ OD600 ratio. (C) EMSAs comparing the DNA-binding activity of NagC and NagC-GlcNAc towards glmR promoter DNA. (D) Quantification of binding affinities.
Figure 4Arg-glycosylation of GlmR improves its GlmS enhancer activity. (A) SDS-PAGE and Western blot analysis of purified proteins used for GlmS activity assays. (B) GlmS activity was measured in the presence of absence of either native or Arg-glycosylated GlmR by measuring the amount of CoASH produced in an enzyme-coupled assay. The GlmS product GlcN6P was acetylated by the yeast GlcN6P N-acetyltransferase 1, GNA-1, to produce GlcNAc6P and CoASH which was measured at 412 nm.
Figure 5Quantification of UDP-GlcNAc levels. Wild-type Salmonella, ΔsseK1, and complemented ΔsseK1 strains were grown overnight in M9 medium. Cell lysates were incubated for 2 h at room temperature with 100 mM SseK1 to hydrolyze UDP-GlcNAc. The UDP was quantified by using a UDP detection reagent (Promega) that converts UDP into ATP to generate light in a luciferase reaction.
Figure 6Working Model. SseK1 Arg-glycosylates NagC to enhance transcriptional activation of glmUS and glmR. SseK1 also glycosylates GlmR to increase GlmS activity, leading to increased levels of UDP-GlcNAc.
Plasmids used in this study.
| Construct | Plasmid | Source |
|---|---|---|
| Flag-SseK1 | pFLAG-CTC- | [ |
| Flag-SseK1 (HEN) | pFLAG-CTC- | [ |
| GST-SseK1 | pET42a- | [ |
| GST-SseK1 (HEN) | pET42a- | [ |
| His-NagC | *pTac- | This study |
| His-GlmS | pTac- | This study |
| His-GlmM | pTac- | This study |
| His-GlmU | pTac- | This study |
| His-GlmR | pTac- | This study |
| His-GNA1 | pTac- | This study |
| His-NagC R25A | pTac- | This study |
| His-NagC R35A | pTac- | This study |
| His-NagC R54A | pTac- | This study |
| His-NagC R59A | pTac- | This study |
| His-GlmR R110A | pTac- | This study |
| His-GlmR R212A | pTac- | This study |
| His-NagC quadruple R/K | pTac- | This study |
| pHG156a- | This study | |
| pHG156a- | This study | |
| pHG156a- | This study | |
*pTac is a pET28a derivative in which the T7 promoter was replaced with the Tac promoter.
Strains used in this study.
| Strain | Source |
|---|---|
| [ | |
| [ | |
| [ | |
| [ | |
| [ | |
| [ | |
| [ | |
| [ | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study | |
| This study |